Literature DB >> 9354267

A ribozyme targeted to cleave the polymerase gene sequences of different foot-and-mouth disease virus (FMDV) serotypes.

Y Stram1, T Molad.   

Abstract

Vaccinations against foot-and-mouth disease virus (FMDV) has dramatically reduced the number of disease outbreaks. Nevertheless, there are still many outbreaks in different regions around the world. In an effort to find new ways to control the disease, ribozymes able to cleave FMDV were designed and tested. In this work we tested the ability of FRZ4, a ribozyme targeted to the viral polymerase gene, to cleave polymerase sequences of several FMDV. Homology analysis was used to choose target sequences which consist of two conserved GUC which lie 15 bases apart and, their flanking sequences. These were the basis for the FRZ4 ribozyme gene sequence that contains two catalytic domains. We show that polymerase sequences from A, Asia 1, C and two different O1 Israeli isolates could be specifically cleaved by FRZ4. It is suggested that FRZ4 can cleave polymerase gene sequences from any FMDV serotype.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9354267     DOI: 10.1023/a:1007954830070

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  17 in total

1.  Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA.

Authors:  K M Lo; M A Biasolo; G Dehni; G Palú; W A Haseltine
Journal:  Virology       Date:  1992-09       Impact factor: 3.616

2.  Ribozymes as potential anti-HIV-1 therapeutic agents.

Authors:  N Sarver; E M Cantin; P S Chang; J A Zaia; P A Ladne; D A Stephens; J J Rossi
Journal:  Science       Date:  1990-03-09       Impact factor: 47.728

3.  A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1.

Authors:  O Yamada; G Kraus; L Luznik; M Yu; F Wong-Staal
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

4.  Activation of HIV-specific ribozyme activity by self-cleavage.

Authors:  M Ventura; P Wang; T Ragot; M Perricaudet; S Saragosti
Journal:  Nucleic Acids Res       Date:  1993-07-11       Impact factor: 16.971

5.  Gene encoding capsid protein VP1 of foot-and-mouth disease virus: a quasispecies model of molecular evolution.

Authors:  J Dopazo; F Sobrino; E L Palma; E Domingo; A Moya
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

6.  Ribozyme cleaves rex/tax mRNA and inhibits bovine leukemia virus expression.

Authors:  G H Cantor; T F McElwain; T A Birkebak; G H Palmer
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

7.  A ribozyme gene and an antisense gene are equally effective in conferring resistance to tobacco mosaic virus on transgenic tobacco.

Authors:  R de Feyter; M Young; K Schroeder; E S Dennis; W Gerlach
Journal:  Mol Gen Genet       Date:  1996-02-25

8.  Cleavage of transcripts of foot and mouth disease virus (FMDV), Asia1 serotype, by ribozymes targeted to the VP3 and VP4 genes.

Authors:  Y Stram; T Molad
Journal:  Virus Genes       Date:  1995-01       Impact factor: 2.332

9.  Inhibition of viral multiplication by hammerhead ribozymes targeted against the polymerase gene of mouse hepatitis virus.

Authors:  A Maeda; T Mizutani; M Hayashi; T Watanabe; S Namioka
Journal:  J Vet Med Sci       Date:  1994-10       Impact factor: 1.267

10.  Identification of amino acid and nucleotide sequence of the foot-and-mouth disease virus RNA polymerase.

Authors:  B H Robertson; D O Morgan; D M Moore; M J Grubman; J Card; T Fischer; G Weddell; D Dowbenko; D Yansura
Journal:  Virology       Date:  1983-04-30       Impact factor: 3.616

View more
  1 in total

1.  Inhibition of foot-and-mouth disease virus replication in vitro and in vivo by small interfering RNA.

Authors:  Wang Pengyan; Ren Yan; Guo Zhiru; Chen Chuangfu
Journal:  Virol J       Date:  2008-07-25       Impact factor: 4.099

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.